Neurogene Inc
NASDAQ:NGNE

Watchlist Manager
Neurogene Inc Logo
Neurogene Inc
NASDAQ:NGNE
Watchlist
Price: 20.59 USD 1.53% Market Closed
Market Cap: 318.9m USD

Neurogene Inc
Tax Provision

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Neurogene Inc
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Neurogene Inc
NASDAQ:NGNE
Tax Provision
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Tax Provision
$735m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Tax Provision
-$1.8B
CAGR 3-Years
-13%
CAGR 5-Years
-28%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Tax Provision
-$1.2B
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Tax Provision
-$773.6m
CAGR 3-Years
-1%
CAGR 5-Years
-29%
CAGR 10-Years
-37%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Tax Provision
-$567.1m
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
1%
No Stocks Found

Neurogene Inc
Glance View

Market Cap
304.2m USD
Industry
Biotechnology

Neurogene Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neurogene Inc., formerly Neoleukin Therapeutics, Inc., is focused on developing genetic medicines for patients and their families affected by rare, devastating neurological diseases. The firm is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. The firm's product candidate, NGN-401, is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic activity while averting transgene overexpression toxicities. The firm is also developing NGN-101 for the treatment of CLN5 Batten disease. The company is advancing multiple discovery-stage candidates leveraging its EXACT transgene regulation technology.

NGNE Intrinsic Value
17.13 USD
Overvaluation 17%
Intrinsic Value
Price

See Also

Back to Top